ProAxsis welcomes Professor Stephen Smith as new Chairman
ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman of the company’s Board of Directors with immediate effect. Stephen has held senior leadership roles in the NHS and academia, including with the University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust. He was responsible for the largest merger […]
New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases
Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) and the European Respiratory Society (ERS), has been published in the latest edition of the European Respiratory Journal2 and demonstrates the potential for NEATstik®, a point-of-care test developed by Belfast-based ProAxsis Limited (www.proaxsis.com), to be used […]
ProAxsis enhances portfolio with new CE Marked Immunoassay
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces that it has successfully registered a CE Mark for its novel ProteaseTag® Active Proteinase 3 Immunoassay. Furthermore, the company confirms an immediate first commercial sale for this new immunoassay. Proteinase 3 is a […]
ProAxsis reports first NEATstik® sale
Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel sputum-based point-of-care test, to a research laboratory conducting an ongoing respiratory clinical trial for a pharmaceutical company. NEATstik® was registered with a CE Mark in the second half of 2017 and utilises the […]
ProAxsis Launches ProteaseTag® Active Plasmin Immunoassay following CE Mark registration
ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology will enable academic and pharmaceutical researchers to specifically measure only the active form of plasmin, a protease associated with fibrinolysis. It is believed that plasmin is involved in the pathogenesis of lung disorders […]
ProAxsis provides update on commercialisation progress
Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in the Titanic Quarter of Belfast, ProAxsis is pleased to provide an update on the commercialisation of its ProteaseTag® technology. The ProteaseTag® Active Neutrophil Elastase Immunoassay was registered with a CE Mark in the latter half of 2016, […]
ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health
ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it will be conducting a collaborative 12-month project with the Northern Ireland Connected Health Innovation Centre (CHIC), based at Ulster University. The project will focus on the development of a quantitative lateral flow device designed to monitor the ongoing clinical status of patients with respiratory diseases […]
ProAxsis appoints first distributor for NE Immunoassay
ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great Britain and Ireland. Founded in 1994, Diagenics supply high quality diagnostic products to NHS and private hospitals, as well as University and industrial biomedical research laboratories throughout the UK region. Dr David Ribeiro, […]
ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test
ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care test for measuring active neutrophil elastase, and has successfully registered the product with a CE Mark. This allows the company to sell the product throughout Europe. NEATstik® is a first-in-class diagnostic tool for the monitoring of lung inflammation […]
ProAxsis technology highlighted in AJRCCM editorial
ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of the American Journal for Respiratory and Critical Care Medicine (AJRCCM). A prospective cohort study led by Dr James Chalmers at the University of Dundee has shown that sputum neutrophil elastase (NE) activity is […]
